MX2018014966A - Peptidos monolipidados resistentes a proteasas. - Google Patents

Peptidos monolipidados resistentes a proteasas.

Info

Publication number
MX2018014966A
MX2018014966A MX2018014966A MX2018014966A MX2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A
Authority
MX
Mexico
Prior art keywords
protease
peptides
resistant
amino acids
lipidated peptides
Prior art date
Application number
MX2018014966A
Other languages
English (en)
Inventor
A Bednarek Maria
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2018014966A publication Critical patent/MX2018014966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención proporciona péptidos resistentes a proteasas, métodos de preparación de tales péptidos, así como composiciones que comprenden péptidos resistentes a proteasas y métodos de tratamiento que utilizan tales péptidos. Se ha determinado que una combinación de lipidación de ciertos residuos de aminoácidos y sustitución de aminoácidos alternativos por aminoácidos naturales y aminoácidos adicionales añadidos a la cadena peptídica produce péptidos resistentes a proteasas.
MX2018014966A 2016-06-09 2017-06-08 Peptidos monolipidados resistentes a proteasas. MX2018014966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347693P 2016-06-09 2016-06-09
PCT/EP2017/063905 WO2017211922A2 (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides

Publications (1)

Publication Number Publication Date
MX2018014966A true MX2018014966A (es) 2019-08-14

Family

ID=59078034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014966A MX2018014966A (es) 2016-06-09 2017-06-08 Peptidos monolipidados resistentes a proteasas.

Country Status (10)

Country Link
EP (1) EP3468987A2 (es)
JP (1) JP2019525732A (es)
KR (1) KR20190017017A (es)
CN (1) CN109195984A (es)
AU (1) AU2017277594A1 (es)
BR (1) BR112018072968A2 (es)
CA (1) CA3025592A1 (es)
IL (1) IL263292A (es)
MX (1) MX2018014966A (es)
WO (1) WO2017211922A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001637PA (en) * 2017-09-22 2020-03-30 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
PE20211417A1 (es) 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
KR20230125093A (ko) 2021-01-20 2023-08-28 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
WO2015086686A2 (en) * 2013-12-13 2015-06-18 Medimmune Limited Protease resistant peptides
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽

Also Published As

Publication number Publication date
IL263292A (en) 2018-12-31
AU2017277594A1 (en) 2019-02-07
WO2017211922A3 (en) 2018-01-18
CN109195984A (zh) 2019-01-11
BR112018072968A2 (pt) 2019-02-19
WO2017211922A2 (en) 2017-12-14
EP3468987A2 (en) 2019-04-17
CA3025592A1 (en) 2017-12-14
KR20190017017A (ko) 2019-02-19
JP2019525732A (ja) 2019-09-12

Similar Documents

Publication Publication Date Title
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
AR125326A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
PH12017502259A1 (en) Protease-resistant lipidated glp-1 analogs
CR20130667A (es) Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
WO2015027259A3 (de) Polypeptid zur hydrolytischen spaltung von zearalenon und/oder zearalenon-derivaten, isoliertes polynukleotid davon sowie einen zusatzstoff enthaltendes polypeptid, verwendung desselben sowie verfahren
EA201990071A1 (ru) Композиция пептидной вакцины
PH12018502465A1 (en) Mic-1 compounds and use thereof
SG10201805039UA (en) Protease resistant peptides
EA201490735A1 (ru) Лечение дегенеративного заболевания сустава
MX2019007152A (es) Peptido novedoso.
SG10201806926YA (en) Method for masking bitterness of composition containing collagen peptide
PH12017501070A1 (en) Peptides and their use in the treatment of skin
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX369195B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
EA201792362A1 (ru) Композиции и способы для лечения целиакии спру
EA202091007A1 (ru) Способ снижения времени восстановления высушенных распылением белковых составов
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
NZ744289A (en) Composition containing amino acids
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
MY197348A (en) A composition for improving memory, learning ability, and cognitive ability
EA201692440A1 (ru) Пролин-специфичная эндопротеаза и ее применение
EA201992057A1 (ru) Персонализированная платформа для идентификации иммуногенного пептида